Investor Relations Home
Download Documentation 2016 Guidance Worksheet
Download Documentation ALN-PCSsc Phase 1 Clinical Results Presentation
Download Documentation Update on ABP-700
Download Documentation ALN-PCSsc Phase 1 Clinical Results Presentation
Download Documentation ABP-700 & MDCO-216 Conference Call Presentation
Corporate Profile
The Medicines Company provides medical solutions to improve health outcomes for patients in acute and intensive care hospitals worldwide. These solutions comprise medicines and knowledge that directly impact the survival and well-being of critically ill patients.
Stock Quote
MDCO (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$49.11
Change (%) Stock is Down 2.34 (4.55%)
Volume2,413,073
Data as of 04/25/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News
DateTitle 
04/26/17The Medicines Company Reports First-Quarter 2017 Financial Results
PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 26, 2017-- The Medicines Company (NASDAQ:MDCO) today announced its business and financial results for the first-quarter ended March 31, 2017. “During the first quarter of 2017, The Medicine Company continued to deliver excellent execution against our 2017 objectives, significantly advancing key development programs, strictly managing cash deployment to enhance our ability to support our products and pipelin... 
Printer Friendly Version
04/26/17The Medicines Company and Alnylam Pharmaceuticals Announce Agreement with FDA on Phase III Clinical Program for Inclisiran
— Pivotal trials will enroll approximately 1,500 subjects randomized to inclisiran versus approximately 1,500 subjects randomized to placebo, with a primary endpoint of LDL-C and an 18-month study period — — NDA submission anticipated at or around the end of 2019 — PARSIPPANY, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 26, 2017-- The Medicines Company (NASDAQ:MDCO) and Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) today announced that T... 
Printer Friendly Version
04/17/17The Medicines Company to Present Data at ECCMID 2017 on Infectious Disease Portfolio Including Investigational Antibiotic Meropenem-Vaborbactam
PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 17, 2017-- The Medicines Company (NASDAQ:MDCO) today announced that data from its portfolio of antimicrobial products and late-stage product candidates will be featured in presentations at the 27th Annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2017) to be held April 22-25, 2017, in Vienna, Austria. The Company will present data on its investigational antibiotic, ... 
Printer Friendly Version
04/12/17The Medicines Company to Announce First-Quarter 2017 Financial Results on April 26, 2017
PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 12, 2017-- The Medicines Company (NASDAQ:MDCO) will host a conference call on Wednesday, April 26, 2017, at 8:30 a.m., Eastern Daylight Time, to discuss first-quarter 2017 financial results and operational developments. The dial-in information to access the call is listed below: U.S./Canada: (877) 359-9508 International: (224) 357-2393 Conference ID: 4094876 A taped replay of... 
Printer Friendly Version
Upcoming Events
DateTitle
04/26/17 8:30 a.m. ET
Q1 2017 The Medicines Company Earnings Conference Call

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.